CSI Market
Sign In | Register

Mereo Biopharma Group Plc (MREO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MREO Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Mereo Biopharma Group Plc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-9.06
Depreciation & amortization0.04
Amortization of Other Assets0.13
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets0.00
Share-based Compensation2.16
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.02
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Sharebased Payments-
Adjustments For Modification Gain On Bank Loan-
Adjustments For Fair Value Remeasurement On Contingent Consideration-
Adjustments For Fair Value Remeasurement Gain On Lease Modification-
Fair Value Remeasurement On Contingent Consideration-
Adjustments For Gains Losses On Change In Fair Value Remeasurement On Warrant-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Increase Decrease In Trade And Other Payables-
Operating Lease Right Of Use Asset Amortization Expense0.13
Interest Income-
Interest Expenses0.01
Increase Decrease In Research And Development Taxes Receivable-0.10
Increase Decrease In Operating Lease Liability-0.20
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.64
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.23
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.27
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.03
Discontinued operations0.00
Net Cash flow from Operating Activities-5.81
Investing Activities
Capital Expenditures0.30
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities-
Cash Flows From Used In Decrease Increase In Shortterm Deposits And Investments-
Interest Received Classified As Investing Activities-
Proceeds From Out Licensing-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.30
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments For Loan And Borrowings Issue Cost Explanatory-
Payments To Acquire Or Redeem Entitys Shares-
Consideration Paid For Transaction Cost On Issuance Of Ordinary Shares-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-0.16
Discontinued operations0.00
Free Cash Flow-5.51
Total Cash Flow-6.22
4 historic quarters locked

Sign in to unlock the full Mereo Biopharma Group Plc cash flow history.

Sign In Create Free Account

About Mereo Biopharma Group Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-343533

Figures are derived from filed reports and may be restated. Historical data is subject to revision.